natgillin/translations-raw huggingface dataset:
Plasmaclearance, fordelingsvolumen og halveringstid er uafhængige af dosis.
Plasma clearance, volume of distribution and half- life are independent of dose.
Plasmaclearancen falder markant ved høje doser; fra cirka 40 l/kg/dag ved dosis på 600 mg/dag til cirka 8 l/kg/dag ved dosis på 2.400 mg.
Plasma clearance decreases markedly at high doses; it falls from approximately 40 l/kg/day at the dose of 600 mg/day to about 8 l/kg/day at the dose of 2,400 mg.
plasmaconcentrationen af
concentrations of dabigatran
Plasmaeksponering (AUC og Cmax) for valdecoxib blev øget (henholdsvis 62% og 19%), når det blev administreret sammen med fluconazol (hovedsagelig en CYP2C9-hæmmer), hvilket viser, at dosis af parecoxib bør reduceres hos de patienter, der er i fluconazolbehandling.
Plasma exposure (AUC and Cmax) to valdecoxib was increased (62% and 19%, respectively) when co- administered with fluconazole (predominantly a CYP2C9 inhibitor), indicating that the dose of parecoxib should be reduced in those patients who are receiving fluconazole therapy.
Plasmaeksponeringen (AUCτ,ss) blev øget med 26 % hos en patient på 42 kg (2,5-percentilen) og reduceret med 22 % hos en patient på 95 kg (97,5-percentilen) sammenlignet med en patient på 62 kg (den mediane legemsvægt for patienterne i den samlede patientpopulation).
Plasma exposure (AUCτ,ss) was increased by 26% for a 42 kg patient (2.5th percentile) and decreased by 22% for a 95 kg patient (97.5th percentile) relative to a patient weighing 62 kg (median body weight of patients in the overall patient population).
Plasmaeksponeringen af migalastat (AUC0-∞) og Cmax steg dosisproportionalt med orale doser fra 50 mg til 1250 mg.
Plasma migalastat exposure (AUC0-∞) and Cmax demonstrated dose-proportional increases at migalastat oral doses from 50 mg to 1,250 mg.
Plasmaeksponeringen af omeprazol (CYP2C19-substrat) 40 mg 1 gang dagligt blev øget med 46% efter administration af valdecoxib 40 mg 2 gange dagligt i 7 dage, mens plasmaeksponeringen af valdecoxib var upåvirket.
Plasma exposure of omeprazole (CYP 2C19 substrate) 40 mg once daily was increased by 46% following administration of valdecoxib 40 mg twice daily for 7 days, while the plasma exposure to valdecoxib was unaffected.
Plasmaeksponeringen af simeprevir (AUC) hos HCV- inficerede patienter var cirka 2-3 gange højere end den, der blev observeret hos de raske deltagere.
Plasma exposure of simeprevir (AUC) in HCV infected patients was about 2- to 3-fold higher compared to that observed in healthy subjects.
Plasmaens halveringstid er 30 til 40 timer.
The plasma half-life is 30–40 hours.
Plasmafarmakokinetiske profiler blev analyseret på dag 1 og på enten dag 7 eller dag 28, hvor plasmakoncentrationerne havde nået steady- state.
Plasma pharmacokinetic profiles were analysed on day 1 and on either day 7 or day 28, by which time plasma concentrations had reached steady state.
Plasmafarmakokinetiske profiler blev analyseret på dag 1 og på enten dag 7 eller dag 28, hvor plasmakoncentrationerne havde nået steady-state.
Plasma pharmacokinetic profiles were analysed on day 1 and on either day 7 or day 28, by which time plasma concentrations had reached steady state.
Plasmaglucose før morgenmad*
Pre-breakfast plasma glucose
Plasmahalveringstiden for levetiracetam hos voksne var 7±1 timer og påvirkedes hverken af dosis, administrationsvej eller gentagen dosering.
The plasma half-life in adults was 7±1 hours and did not vary either with dose, route of administration or repeated administration.
Plasmahalveringstiden for sildenafil blev estimeret til 4,2-4,4 timer i området 10-70 kg legemsvægt og viste ikke forskelle af klinisk relevans.
10 to 70 kg of body weight and did not show any differences that would appear as clinically relevant.
Plasmakoncentration af
Plasma trough
plasmakoncentration af methadon
plasma levels of methadone and
plasmakoncentration af simeprevir.
concentrations of simeprevir are expected.
plasmakoncentration er ikke
Efavirenz concentrations not measured,
plasmakoncentration er ikke
Interaction not studied.
Plasmakoncentration for dabigatran viste en bieksponentiel nedbrydning med en middel halveringstid på 11 timer hos raske ældre.
Plasma concentrations of dabigatran showed a biexponential decline with a mean terminal half-life of 11 hours in healthy elderly subjects.
Plasmakoncentrationen af
failure)
plasmakoncentrationen af
plasma concentrations of
Plasmakoncentrationen af
Plasma concentrations of digoxin
plasmakoncentrationen af
reduced plasma
Plasmakoncentrationen af AsIII falder fra maksimal plasmakoncentration på en bifasisk måde med en gennemsnitlig terminal eliminationshalveringstid på 10-14 timer.
The plasma concentration of AsIII declines from peak plasma concentration in a biphasic manner with a mean terminal elimination half-life of 10 to 14 hours.
Plasmakoncentrationen af atazanavir kan falde pga. gastrisk pH-stigning, hvis antacida, inklusive lægemidler med buffer, administreres samtidigt med EVOTAZ.
Reduced plasma concentrations of atazanavir may be the consequence of increased gastric pH if antacids, including buffered medicinal products, are administered with EVOTAZ.
plasmakoncentrationen af boceprevir blev reduceret, når det blev co- administreret med en NNRTI med en lignende metaboliseringsvej som nevirapin.
Plasma trough concentrations of boceprevir were decreased when administered with an NNRTI with a similar metabolic pathway as nevirapine.
plasmakoncentrationen af ciclosporin, sirolimus
plasma concentrations of cyclosporine,
plasmakoncentrationen af disse
antidepressant plasma concentrations
Plasmakoncentrationen af frit aflibercept faldt derefter til værdier under eller nær den nedre kvantificieringsgrænse, sædvanligvis inden for en uge; ikke-detekterbare koncentrationer blev nået inden næste administration 4 uger senere hos alle patienter.
Thereafter, plasma concentrations of free aflibercept declined to values below or close to the lower limit of quantitation generally within one week; undetectable concentrations were reached before the next administration after 4 weeks in all patients.
plasmakoncentrationen af HMG-CoA-
concentrations of the HMG Co-A reductase
Plasmakoncentrationen af ibandronsyre øges dosisproportionalt efter intravenøs administration af 0,5- 6 mg.
Plasma concentrations of ibandronic acid increase in a dose-proportional manner after intravenous administration of 0.5 mg to 6 mg.
Plasmakoncentrationen af linagliptin aftager tre-fasisk med en lang terminal halveringstid (terminal halveringstid for linagliptin på mere end 100 timer), som overvejende er relateret til linagliptins mætbare, tætte binding til DPP-4, uden at bidrage til lægemiddelakkumulation.
Plasma concentrations of linagliptin decline in a triphasic manner with a long terminal half-life (terminal half-life for linagliptin more than 100 hours), that is mostly related to the saturable, tight binding of linagliptin to DPP-4 and does not contribute to the accumulation of the drug.
Plasmakoncentrationen af metabolitten PpIX var generelt lav hos alle patienter, og der blev ikke observeret en tydelig stigning i PpIX-plasmakoncentrationen efter applikation af Ameluz.
The plasma concentrations of metabolite PpIX were generally low in all patients and in none of the patients an obvious increase of PpIX plasma concentrations was observed after Ameluz application.
Plasmakoncentrationen af pitavastatin kan øges ved samtidig administration af EVOTAZ.
Plasma concentrations of pitavastatin may be increased if co-administered with EVOTAZ.
plasmakoncentrationen af sildenafil og
the concentration of these medicines.
Plasmakoncentrationen af trazodon kan stige.
Saquinavir/ritonavir concentrations
Plasmakoncentrationen af ubundet dronedraron var fordoblet hos forsøgspersoner med moderat nedsat.
In subjects with moderate hepatic impairment, dronedarone unbound exposure is increased by 2-fold.
Plasmakoncentrationen af visse anti-epileptiske lægemidler, så som phenytoin og carbamazepin, kan stige ved samtidig administration af Clomicalm.
Plasma levels of certain anti- epileptic drugs, such as phenytoin and carbamazepine, may be increased by co-administration with Clomicalm.
Plasmakoncentrationen af visse anti-epileptiske lægemidler, så som phenytoin og carbamazepin, kan stige ved samtidig administration af Clomicalm.
Plasma levels of certain anti- epileptic drugs, such as phenytoin and carbamazepine, may be increased by coadministration with Clomicalm.
Plasmakoncentrationen af vortioxetin var ca. dobbelt så høj hos patienter med nedsat CYP2D6- metabolisme i forhold til patienter med normal metabolisme.
The plasma concentration of vortioxetine was approximately two times higher in CYP2D6 poor metabolisers than in extensive metabolisers.
Plasmakoncentrationen eller andre farmakodynamiske markører for disse samtidigt indgivne lægemidler med et smalt terapeutisk indeks skal monitoreres, når behandling med eluxadolin initieres eller afbrydes.
The concentration of these co-administered medicinal products with a narrow therapeutic index or their other pharmacodynamic markers should be monitored when concomitant use with eluxadoline is initiated or discontinued.
Plasmakoncentrationen for atazanavir kan nedsættes som følge af en reduktion af cobicistats plasmakoncentration, hvilket kan betyde tab af terapeutisk effekt og udvikling af resistens.
Atazanavir plasma concentrations may decrease as a consequence of a reduction in cobicistat plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Plasmakoncentrationen for lægemidler, der metaboliseres via disse enzymsystemer kan eventuelt være nedsat når de gives samtidig med nevirapin.
Compounds using this metabolic pathway may have decreased plasma concentrations when co- administered with nevirapine.
Plasmakoncentrationen for lægemidler, der metaboliseres via disse enzymsystemer kan eventuelt være nedsat når de samtidig gives med nevirapin.
Compounds using this metabolic pathway may have decreased plasma concentrations when co- administered with nevirapine.
Plasmakoncentrationen for phenytoin, phenobarbital og andre antikonvulsiva, som er substrater for CYP-isoenzymer, kan eventuelt falde eller stige, når disse administreres samtidigt med efavirenz.
There is a potential for reduction or increase in the plasma concentrations of phenytoin, phenobarbital and other anticonvulsants that are substrates of CYP450 isoenzymes when co- administered with efavirenz.
Plasmakoncentrationen stiger proportionalt med dosis efter oral (100-800 mg) og i.v. (50-300 mg) administration.
The plasma concentration increases proportionally with dose after oral (100-800 mg) and i.v. (50-300 mg) administration.
plasmakoncentrationen, mens
concentrations while nevirapine
plasmakoncentrationen, som kan
plasma concentrations which may
Plasmakoncentrationens tidsprofil for intravenøst indgivet gadofosveset svarer til en åben to- kompartmentsmodel.
The plasma concentration-time profile of intravenously administered gadofosveset conforms to a two- compartment open model.
Plasmakoncentrationer af
Plasma concentrations of
Plasmakoncentrationer af
Plasma concentrations of OATP
Plasmakoncentrationer af atorvastatin, pitavastatin, fluvastatin, pravastatin eller rosuvastatin forventes at stige, når de administreres samtidig med atazanavir/cobicistat eller darunavir/cobicistat.
Plasma concentrations of atorvastatin, pitavastatin, fluvastatin, pravastatin or rosuvastatin are expected to increase when co-administered with atazanavir/cobicistat or darunavir/cobicistat.
Plasmakoncentrationer af bosentanmetaboliter steg til omkring det dobbelte hos disse patienter i sammenligning med personer med normal nyrefunktion.
Plasma concentrations of bosentan metabolites increased about 2-fold in these patients as compared to subjects with normal renal function.
Plasmakoncentrationer af colchicin kan øges ved samtidig administration af cobicistat.
Concentrations of these immunosuppressants may be increased when co-administered with cobicistat.
Plasmakoncentrationer af ertapenem er sammenlignelig hos mænd og kvinder.
The plasma concentrations of ertapenem are comparable in men and women.
Plasmakoncentrationer af glycopyrronium faldt på multifasisk vis.
Glycopyrronium plasma concentrations declined in a multi-phasic manner.
plasmakoncentrationer af pitavastatin og
pitavastatin and pravastatin are expected.
plasmakoncentrationer er lavere
are lower with antacids due to
plasmakoncentrationer kan falde
concentrations may decrease due
plasmakoncentrationer kan falde på
therapy should be monitored and
Plasmakoncentrationer over 0,2 g/ml af ceftiofur og dets metabolitter opretholdes i en passende lang periode.
Plasma concentrations above 0.2 µg/ml of ceftiofur and its metabolite are maintained for an appropriate period of time.
Plasmakoncentrationer ved steady state er proportionelle med dosis for ataluren-doser mellem 10 og 50 mg/kg, og der ses ingen akkumulering efter gentagen dosering.
Steady-state plasma concentrations are dose-proportional for ataluren doses between 10 and 50 mg/kg, and no accumulation is observed after repeated dosing.
Plasmakoncentrationer ved steady-state opnås på dag 6 ved en dosis på 300 mg (en gang dagligt efter en initialdosis på to gange dagligt på dag 1).
Steady- state plasma concentrations are attained by Day 6 at the 300 mg dose (once daily after twice daily loading dose at Day 1).
Plasmakoncentrationer ↑ Kortisolniveauer ↓ 86%
Plasma concentrations ↑ Cortisol levels ↓ 86
Plasmakoncentrationer, der er veltolerede hos dyr, er mindst 62 gange (Cmax) og 104 gange (Cavg) højere end plasmakoncentrationen hos pædiatriske SJIA-patienter behandlet med op til 4 mg/kg subkutant hver 4. uge.
Plasma concentrations that are well tolerated in animals exceed at least 62-fold (Cmax) and 104-fold (Cavg) the plasma concentrations in paediatric SJIA patients, treated with up to 4 mg/kg via the subcutaneous route every 4 weeks.
plasmakoncentrationerne af
concentrations of coumarins that
plasmakoncentrationerne af
the plasma concentrations of
Plasmakoncentrationerne af atazanavir, darunavir eller boceprevir kan falde ved samtidig administration.
Atazanavir, darunavir or boceprevir plasma concentrations may decrease upon co-administration.
Plasmakoncentrationerne af den aktive metabolit blev reduceret med 20 % (initial mætningsdosis) og 14 % (vedligeholdelsesdosis) under samtidig behandling med 80 mg pantoprazol en gang daglig.
The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced (maintenance dose) during concomitant treatment with pantoprazole 80 mg once daily.
Plasmakoncentrationerne af DM1 og DM1-holdige katabolitter (Lys-MCC-DM1 og MCC-DM1) var lave og sammenlignelige for patienter med og uden nedsat leverfunktion.
Plasma concentrations of DM1 and DM1-containing catabolites (Lys-MCC-DM1 and MCC-DM1) were low and comparable between patients with and without hepatic impairment.
Plasmakoncentrationerne af doxorubicin og dets metabolit, doxorubicinol, kan forøges, når doxo- rubicin indgives sammen med ciclosporin, verapamil, paclitaxel eller andre stoffer, der hæmmer P- glykoprotein (P-gp).
Plasma levels of doxorubicin and its metabolite, doxorubicinol, may be increased when doxorubicin is administered with cyclosporin, verapamil, paclitaxel or other agents that inhibit P-glycoprotein (P-Gp).
plasmakoncentrationerne af midazolam at
expected to be significantly higher when
Plasmakoncentrationerne af nelfinavir kan reduceres ved samtidig brug af urtepræparatet perikon (Hypericum perforatum).
Concomitant use of tadalafil and nelfinavir may increase plasma levels of tadalafil.
Plasmakoncentrationerne af nelfinavir kan reduceres ved samtidig brug af urtepræparatet perikon (Hypericum perforatum).
Plasma levels of nelfinavir can be reduced by concomitant use of the herbal preparation St. John’s wort (Hypericum perforatum).
Plasmakoncentrationerne af nelfinavir, som fortrinsvis metaboliseres af CYP2C19 og kun delvis af CYP3A4, øges kun lidt ved samtidig administration af ritonavir og derfor er det ikke nødvendigt at administrere nelfinavir samtidig med lavdosis ritonavir.
Plasma levels of nelfinavir, which is metabolised predominantly by CYP2C19 and only partially by CYP3A4, are not greatly increased by co-administration with ritonavir, and therefore nelfinavir does not require co-administration with low-dose ritonavir..
Plasmakoncentrationerne af riociguat er reducerede hos rygere sammenlignet med ikke-rygere.
Plasma concentrations of riociguat in smokers are reduced compared to non-smokers.
Plasmakoncentrationerne af riociguat hos rygere er reduceret i forhold til ikke-rygere.
Plasma concentrations of riociguat in smokers are reduced compared to non-smokers.
Plasmakoncentrationerne falder hurtigt, og nateglinid’s elimineringshalveringstid var gennemsnitligt typisk på 1,5 timer i alle undersøgelser af Trazec med frivillige forsøgspersoner og type 2 diabetikere.
Plasma concentrations decline rapidly and the elimination half-life of nateglinide typically averaged 1.5 hours in all studies of Trazec in volunteers and type 2 diabetic patients.
Plasmakoncentrationerne for
Plasma concentrations of tipranavir
Plasmakoncentrationerne kan være øget på grund af P-glycoprotein- hæmning af lopinavir/ritonavir.
Plasma concentrations may be increased due to P-glycoprotein inhibition by lopinavir/ritonavir.
Plasmakoncentrationerne var ikke forhøjede hos patienter med forhøjet aspartataminotransferase (AST), basisk phosphatase eller bilirubin på grund af levermetastaser (se pkt.
Plasma concentrations were not increased in patients with elevated aspartate transaminase (AST), alkaline phosphatase or bilirubin due to liver metastases (see section 5.2).
Plasmakreatinin-niveauet kan stige initialt pga. hæmning af den renale tubulære udskillelse af kreatinin, og dette er ikke nødvendigvis tegn på forværring af nyrefunktionen.
Plasma creatinine levels may rise initially due to inhibition of the renal tubular excretion of creatinine and are not necessarily indicative of a deterioration in renal function. .
Plasmakreatininværdier skal måles henholdsvis før og 7 dage efter initiering af dronedaron.
Plasma creatinine values should be measured prior to and 7 days after initiation of dronedarone.
Plasmaniveauer af cargluminsyre blev målt hos patienter i alle aldersgrupper, fra nyfødte spædbørn til halvvoksne, behandlet med forskellige daglige doser (7 – 122 mg/kg/dag).
Plasma levels of carglumic acid were measured in patients of all age categories, from newborn infants to adolescents, treated with various daily doses (7 – 122 mg/kg/day).
Plasmaniveauet af lidocain og prilocain hos de mandlige og kvindelige deltagere var under det niveau, der er forbundet med toksicitet (5 000 ng/ml).
The plasma levels of lidocaine and prilocaine in male and female subjects were below the level associated with toxicity (5000 ng/ml).
Plasmaniveuaet af 3- OMD blev klart og dosisafhængigt nedsat af tolcapon, når det blev indgivet med levodopa/AADC-I (aromatisk decarboxylasehæmmer) (benserazid eller carbidopa).
Plasma levels of 3- OMD were markedly and dose-dependently decreased by tolcapone when given with levodopa/AADC-I (aromatic amino acid decarboxylase - inhibitor) (benserazide or carbidopa).
Plasmaproteinbinding af cladribine udgør gennemsnitligt 25% med en bred interindividuel variation (5-50%).
Plasma protein binding of cladribine is 25% on average, with a wide interindividual variation (5-50%).
Plasmaproteinbinding er 85- 87 %.
Plasma protein binding is at 85-87 %.
Plasmaproteinbinding kunne ikke måles på grund af ustabilitet, men baseret på osimertinibs fysik-kemiske egenskaber er plasmaproteinbindingen sandsynligvis udtalt.
Plasma protein binding could not be measured due to instability, but based on the physicochemical properties of osimertinib plasma protein binding is likely to be high.
Plasmaproteinbindingen af (+)-(R) og (-)-(S) enantiomerer blev påvist at være henholdsvis 55 % og 65 %.
The plasma protein binding of the (+)-(R) and (-)-(S) enantiomers was found to be 55% and 65% respectively.
Plasmaproteinbindingen af 14C-mærket abirateron i humant plasma er 99,8 %.
The plasma protein binding of 14C-abiraterone in human plasma is 99.8%.
Plasmaproteinbindingen af atosiban er hos gravide kvinder 46 - 48%.
Plasma protein binding of atosiban is 46 to 48% in pregnant women.
Plasmaproteinbindingen af naloxegol hos mennesker var lav, og den ubundne fraktion rangerede fra 80 % til 100 %.
Plasma protein binding of naloxegol in humans was low and the fraction unbound ranged from 80% to 100%.
Plasmaproteinbindingen af tipiracilhydrochlorid var under 8%.
Plasma protein binding of tipiracil hydrochloride was below 8%.
Plasmaproteinbindingen var lav, omkring 40%.
Plasma protein binding was low, approximately 40%.
Plasmaprøver blev taget indtil 56 dage (patienter) eller 36 dage (frivillige) efter injektion.
Plasma samples were obtained up to 56 days (patients) or 36 days (volunteers) post injection.
Plasmaprøverne tilberedes straks ved centrifugering i en nedkølet centrifuge (4C).
Plasma samples should immediately be prepared by centrifugation in a pre-cooled centrifuge (4°C).
Plasmasalicylatkoncentrationer over 300 mg/l (1,67 mmol/l) tyder på forgiftning.
Plasma salicylate concentrations above 300 mg/l (1.67 mmol/l) suggest intoxication.
Plasmaurinsyre < 0,360 mmol/l (< 6 mg/dl) i mindst 80 % af tiden i måned 3 og 6
Plasma Uric Acid < 6 mg/dl for at Least 80% of the Time During Months 3 and 6
plastbakkens forsegling er beskadiget eller åbnet.
The sealed plastic tray is damaged or opened.
plastbeholder (HDPE)
bottle (HDPE)
Plastbeholder (HDPE) med PP-skruelåg (polypropylen) med 100 filmovertrukne tabletter.
HDPE bottles of 100 film-coated tablets with a PP screw cap.
PLASTBEHOLDER OG BLYBEHOLDER
PLASTIC JAR and LEAD CONTAINER
Plastbeholderen er forsynet med et børnesikret låg, der åbnes som følger:
The plastic bottle comes with a child resistant cap and should be opened as follows:
plastdåse (HDPE)
bottle (HDPE)
Plaster
Patch
plaster på 28 cm2 indeholder 8,4 mg testosteron og afgiver 300 mikrogram testosteron på 24 timer.
patch of 28 cm2 contains 8.4 mg of testosterone and provides 300 micrograms per 24 hours.
Plasteret bør ikke udsættes for eksterne varmekilder (fx kraftigt sollys, sauna, solarium) i længre perioder.
The patch should not be exposed to any external heat sources (e.g. excessive sunlight, saunas, solarium) for long periods of time.
Plasteret er beregnet til at blive siddende under disse former for aktivitet.
The patch is designed to stay in place during these types of activities.
Plasteret kan anvendes i hverdagssituationer, herunder badning og varmt vejr.
The patch can be used in everyday situations, including bathing and during hot weather.
Plasteret kan blive siddende på huden i op til syv dage afhængigt af kemoterapiens varighed, og man skal vente med at
The patch can remain on the skin for up to seven days depending on the duration of the
Plasteret klæbes godt fast på balderne, maveregionen (abdomen), overarmene eller den øverste del af ryggen, men ikke på brystet eller på rød eller irriteret hud eller hud med rifter.
The patch must be firmly applied to the buttock, abdomen (tummy), upper arm or upper back, but not on the breast, or on skin that is red, irritated or cut.
Plasteret må ikke klippes i stykker.
The patch should not be cut into pieces.
Plasteret skal anbringes på et rent, tørt, intakt, sundt hudområde på mave, lår, hofter, side, skulder eller overarm.
The patch should be applied to clean, dry, intact healthy skin on the abdomen, thigh, hip, flank, shoulder, or upper arm.
Plasteret skal klæbe ordentligt til huden, for at det kan fungere korrekt.
To work properly the patch must stick firmly to your skin.
Plasteret skal presses fast mod huden med håndfladen i 20-30 sekunder, så det klæber godt.
The patch should be pressed down firmly with the palm of the hand for about 20 to 30 seconds, so that it sticks well.
Plasteret skal trykkes fast, indtil kanterne klæber godt.
Press the patch down firmly until the edges stick well.
Plasteret trykkes godt ned i mindst 30 sekunder med håndfladen , indtil kanterne sidder godt fast.
The patch should be pressed down firmly for at least 30 seconds using the palm of the hand until the edges stick well.